详情页

当前位置：首页 > 详情页

Analysis of the Relationship between Scleritis and T Cell Activation in Patients with Hepatocellular Carcinoma Treated with PD-1 Carrelizumab

11| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Optometry, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China. [2]Department of Optometry, Hebei Medical University, Shijiazhuang 050011, China. [3]Department of Oncology, the First Hospital of Hebei Medical University, Shijiazhuang 050011, China. [4]Department of Clincal Medicine, Hebei Medical University, Shijiazhuang 050011, China.

出处：

DOI：

ISSN：

摘要：

In order to explore the function of inhibiting the immune effect, the relationship between programmed death receptor 1 (PD-1) carrelizumab in the treatment of hepatocellular carcinoma-induced scleritis and T cell activation is investigated. A total of 120 patients with primary liver cancer treated in the department of oncology of our hospital from July 2020 to January 2022 are selected and treated with carrelizumab. According to the occurrence of PD-1 carrelizumab treatment, the patients are divided into the scleritis group and nonscleritis group. The levels of T cells, PD-1, PD-L1 proteins, and serum inflammatory factors at different time points are compared. The experimental results show that the occurrence of scleritis after liver cancer treatment with PD-1 carrelizumab is closely associated with Treg cells, the percentage of Th17 cells, the expression of PD-1, PD-L1 proteins, and inflammatory factors. It is clearly evident that PD-1 carrelizumab can increase the risk of scleritis by affecting T cell activation.Copyright © 2022 Yazhen Yuan et al.

语种：

WOS：

PubmedID：

中科院分区：

出版当年[2022]版：

大类 | 4 区医学

小类 | 4 区核医学

最新[2025]版：

无

影响因子： 0 最新[2024版] 0 最新五年平均 0 出版当年[2022版] 0 出版当年五年平均 3.009 出版前一年[2021版]

第一作者：

第一作者机构： [1]Department of Optometry, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：